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Heat-killed (HK) Mycobacterium obuense (NCTC13365) is currently being evaluated 
in the clinic as an immunotherapeutic agent for cancer treatment. Yet, the molecu-
lar underpinnings underlying immunomodulatory properties of HK M. obuense are 
still largely undefined. To fill this void, we sought to perform immunophenotyping, 
chemokine/cytokine release analysis and genome-wide characterization of monocyte- 
derived macrophages (MDM) in which monocytes were originally isolated from healthy 
donors and differentiated by HK M. obuense (Mob-MDM) relative to macrophage 
colony-stimulating factor (M-MDM) and granulocyte/macrophage colony-stimulating 
factor (GM-MDM). Immunophenotyping and cytokine release analysis revealed down-
regulated surface expression of CD36, decreased spontaneous release of CCL2 and 
increased spontaneous secretion of CCL5, CXCL8/IL-8, IL-6, and TNF-α in Mob-MDM 
relative to M-MDM and GM-MDM. Analysis of cytostatic activity showed that Mob-MDM 
exhibited similar growth inhibitory effects on immortalized and malignant epithelial cells 
compared with GM-MDM but at an elevated rate relative to M-MDM. To understand 
global cues in Mob-MDM, we performed comparative RNA-sequencing (RNA-Seq) 
analysis of Mob-MDM relative to GM-MDM and M-MDM (n =  4 donors). Clustering 
analysis underscored expression profiles (n = 256) that were significantly modulated in 
Mob-MDM versus both M-MDM and GM-MDM including, among others, chemokines/
cytokines and their receptors, enzymes and transcriptions factors. Topological func-
tional analysis of these profiles identified pathways and gene sets linked to Mob-MDM 
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phenotype including nitric oxide production, acute phase response signaling and 
microbe recognition pathways as well as signaling cues mediated by the proinflam-
matory cytokine, interferon-gamma, and the intracellular pattern recognition receptor, 
nucleotide-binding oligomerization domain-containing protein 2. Taken together, our 
study highlights molecular immune phenotypes and global signaling cues in Mob-MDM 
that may underlie immunomodulatory properties of HK M. obuense. Such properties 
could be of valuable use in immunotherapy approaches such as adoptive cell therapy 
against cancer.
Keywords: monocyte-derived macrophages, heat-killed mycobacteria, Mycobacterium obuense, rna sequencing, 
cD molecules, cytokines, chemokines
as well as chronic infectious, inflammatory, and autoimmune 
diseases. It is well established that mycobacteria exert significant 
immunomodulatory effects (26, 27). For instance, bacillus 
Calmette–Guerin, an attenuated live strain of Mycobacterium 
bovis, induces potent Th-1 immune responses and has proven to 
be highly efficacious in the adjuvant treatment of non-muscle-
invasive bladder cancer (28, 29). Another mycobacterium, M. 
vaccae, in the form of a heat-killed (HK) preparation, is able to 
correct Th-2/Th-1 imbalance through multifaceted effects such as 
stimulating cytotoxic T-cells (30), enhancing the antitumor activ-
ity of γδ T-cells (31) and downregulating Th-2 immune responses 
(32–34). As such, the immunotherapeutic potential of HK M. 
vaccae has been evaluated in the pathological setting including 
allergy, tuberculosis (26, 35) and a range of cancers such as 
melanoma (36) and those of the prostate (37), lung (38, 39), and 
kidney (40). Recently, HK M. obuense (NCTC13365) preparation 
has garnered interest as a promising immunotherapeutic agent 
for cancer (41, 42). In a phase I clinical study, HK M. obuense 
was shown to be safe and well tolerated in patients with advanced 
stage melanoma (42). More recently, a randomized phase II study 
revealed that HK M. obuense, used as an adjunctive immuno-
therapeutic agent, was well-tolerated and resulted in significant 
improvement in the clinical outcome of patients with metastatic 
pancreatic cancer (41). Underlying these therapeutic properties 
may be the impact of HK M. obuense on various components of 
the innate immune system (31, 43); for example HK M. obuense 
augmented the cytotoxic activity of “innate-like” γδ T cells (31) 
as well as regulated the surface expression of various receptors 
on monocytes, neutrophils (43), and dendritic cells (DCs) (44).
While HK mycobacteria have offered promising clinical 
applications, the molecular cues they impinge on innate 
immune cells is not yet well defined. To fill this void, we sought, 
first, to assess whether HK M. obuense could induce monocyte 
differentiation into Mφ and second, to perform phenotypic and 
genome-wide surveys of monocytes differentiated into Mφ in 
the presence of HK M. obuense (Mob-MDM) as compared to 
M-MDM and GM-MDM. We characterized cell surface profiles 
and chemokine/cytokine release patterns in Mob-MDM some 
of which were shared with those of M-MDM and/or GM-MDM. 
Further, whole-transcriptome sequencing coupled with func-
tional pathways and gene-gene network analysis delineated 
contextual expression profiles that are significantly linked to 
Mob-MDM, indicative of an overall augmented proinflamma-
tory M1-like Mφ phenotype. Our findings point to global effects 
inTrODUcTiOn
Macrophages (Mφ) are key members of the mononuclear 
phagocytic system with fundamental roles in the development, 
repair and homeostasis of tissues (1, 2). Tissue Mφ are sustained 
through either local proliferation of cells or the recruitment of 
blood monocytes which in turn differentiate into Mφ (3, 4). Based 
on their activation/polarization state, Mφ are broadly classified 
into M1 and M2 types which represent the polar states of a func-
tional continuum (5).
M1-Mφ, are proinflammatory, promote T-helper 1-type immune 
responses and possess strong antimicrobial and antitumor capaci-
ties. On the contrary, M2-Mφ, which are anti-inflammatory, pro-
mote Th2-type immune responses and support cell proliferation 
and tissue repair as well as contribute to angiogenesis and tumor 
progression (6–9). Accumulating evidence points to important 
roles for the microenvironment in modulating the phenotypic 
and functional heterogeneity of Mφ (10). Of note, macrophage 
colony-stimulating factor (M-CSF) and granulocyte/macrophage 
colony-stimulating factor (GM-CSF) are key growth factors 
involved in the development of monocyte-derived macrophages 
(MDM) (11, 12). Earlier reports suggest that unpolarized/
steady-state Mφ developed in vitro in the presence of GM-CSF 
(GM-MDM) or M-CSF (M-MDM) would exhibit different 
phenotypes suggestive of M1-like or M2-like phenotypes, respec-
tively (13–15). Generation of polarized GM-MDM (M1-Mφ) or 
M-MDM (M2-Mφ) in vitro requires additional stimulation with 
inflammatory stimuli/type 1 cytokine or with type 2 cytokines, 
respectively (16–18). Evidently, unpolarized M-MDM have been 
reported in various studies to result in Mφ which constitutively 
express selected genes, secrete certain cytokines/chemokines 
and/or express surface receptors that are quite distinct from those 
detected in unpolarized GM-MDM (14, 19–21). Despite the fact that 
GM-CSF was originally defined as a hematopoietic growth factor, 
several reports have demonstrated that monocytes differentiated 
into Mφ in the presence of GM-CSF (unpolarized GM-MDM) 
spontaneously release inflammatory cytokines/chemokines, 
whereas unpolarized M-MDM either do not release or release 
some of these molecules at significantly lower levels (16, 22, 23). 
Furthermore, the role of GM-CSF has been well described in 
several inflammatory diseases, including rheumatoid arthritis 
and experimental autoimmune encephalomyelitis (24, 25).
Over the past two decades, there has been substantial interest 
in identifying novel immunomodulatory agents to treat cancer 
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of HK M. obuense on the immunophenotype and transcriptome 
of human innate immune cells and, thus, offer new insights on 
the immunomodulatory properties of HK M. obuense that may 
be gauged for new immunotherapeutic strategies.
MaTerials anD MeThODs
antibodies and reagents
Mouse antihuman fluorescein isothiocyanate (FITC)-conjugated 
CD40 (clone 5C3), CD64 (clone 10.1), CD195 (clone 2D7/
CCR5), CD197 (clone 150503); phycoerythrin (PE)-conjugated 
CD36 (clone CB38), CD80 (clone L307.4), CD163 (clone 
GHI/61), CD206 (clone 19.2); PE-Cyanine 7 (Cy7)-conjugated 
CD16 (clone 3G8); peridinin chlorophyll protein complex (Per-
CP)-conjugated CD14 (clone MφP9), HLA-DR (Clone L243); 
allophycocyanin (APC)-conjugated CD1a (clone HI149), CD32 
(clone FLI8.26), CD86 (clone 2331), HLA-ABC (clone G46-
2.6) antibodies as well as mouse FITC-conjugated IgG1 (clone 
MOPC-21), IgG2a (clone G155-178); PE-conjugated IgG1 
(clone MOPC-21); Per-CP conjugated IgG2a (clone X39), IgM 
(clone G155-228); and APC-conjugated IgG1 (clone MOPC-21) 
isotype control antibodies were obtained from BD Biosciences. 
Sterile vials of HK M. obuense (NCTC13365) suspended in 
borate-buffered saline (pH 8.0) at 50 mg/ml were manufactured 
by BioElpida and applied at a final concentration of 30 µg/ml. 
M-CSF and GM-CSF were applied at final concentrations of 
100 ng/ml (R&D Systems).
collection of Blood from healthy Donors
Peripheral blood samples (200–250  ml) were obtained from 
healthy adult donors through the blood bank at Nini Hospital, 
Lebanon. All donors provided a written informed consent prior 
to participation in this study. Blood was collected in citrate-
phosphate-dextrose-adenine containing blood collection bags 
and stored at room temperature for 1–2 h prior to usage. All of the 
procedures used in the present study were approved by the insti-
tutional review board at the University of Balamand and by the 
research ethics committee at the Faculty of Science, Engineering 
and Computing at Kingston University.
isolation of Monocytes and generation  
of MDM
Peripheral blood mononuclear cells (PBMCs) were separated 
from blood using the standard Ficoll-Paque density gradient 
method as previously described (43). PBMCs were seeded into 
culture flasks at a density of 1.5 × 106 cells/ml and incubated over-
night at 37°C in a 5% CO2 humidified incubator. Later, cells were 
washed extensively and adherent monocytes were allowed to dif-
ferentiate for 5 days into Mφ in complete RPMI growth medium 
[supplemented with 7.5% heat-inactivated pooled human AB 
serum (ZenBio), 2  mM l-glutamine, 100  U/ml penicillin, and 
100 µg/ml streptomycin (Sigma)] in the presence of 100 ng/ml 
M-CSF, 100 ng/ml GM-CSF (16, 23) or 30 µg/ml HK M. obuense 
to generate M-MDM, GM-MDM, and Mob-MDM, respectively. 
The viability of MDM was ~80% as determined by the trypan 
blue dye exclusion method. MDM purity, as assessed by flow 
cytometry, was >85% with the remaining of cells consisting 
primarily of lymphocytes.
immunophenotyping of MDM
To analyze cell surface receptor expression, 1 × 105 MDM were 
preincubated with 10% human serum AB for 20 min at 4°C to 
ensure effective Fc receptor blocking. MDM were then incubated 
with optimized concentrations of antigen-specific or matching 
isotype control antibodies for 25 min at 4°C in the dark, washed 
with cell wash solution (BD Biosciences) and finally resuspended 
in 1% paraformaldehyde solution (Sigma). A total of 10,000 
MDM were analyzed by a FACSCalibur flow cytometer (BD 
Biosciences) using the Cell Quest Pro software (BD Biosciences). 
Viable MDM were gated based on their side scatter (SSC) and 
forward scatter (FSC) properties. Cell surface receptor expres-
sion was reported as the percentage and as the mean fluorescence 
intensity (MFI) of receptor-positive MDM.
Quantification of chemokines, cytokines, 
growth Factors, and nitric Oxide
Adherent MDM were washed extensively with cold PBS and 
detached by incubation in cold RPMI and gentle scraping. MDM 
were seeded in 24-well culture plates at a density of 3 × 105 cells/
well/ml and cultured in complete RPMI growth medium for 
24 h at 37°C in a 5% CO2 humidified incubator. For the quan-
tification of total nitrite levels, RPMI medium was replaced by 
phenol red-free DMEM/F12 medium (Sigma). After 24 h, MDM 
culture supernatants were collected and stored at −80°C for later 
analysis. Levels of human CCL2, CCL5, CCL22, CXCL8/IL-8, 
CXCL9, IL-6, IL-10, IL-12 (p40), IL-12 (p70), IL-23 (p19/p40), 
M-CSF, TGF-β1, TNF-α, total nitric oxide (total nitrite), and 
VEGF were quantified in MDM cell culture supernatants using 
commercially available ELISA kits and total nitric oxide kit fol-
lowing the manufacturer’s procedures (R&D Systems).
assessment of MDM cytostatic activity
HaCaT (kindly provided by Dr. Julnar Usta, American University 
of Beirut, Lebanon) or BxPC3 (kindly provided by Dr. Androulla 
Elia, St. George’s University of London, UK) cells were seeded 
in a 96-well plate at a density of 2.5 × 103 and 5 × 103 cells/well, 
respectively, and were allowed to adhere for 1 h at 37°C in a 5% 
CO2 humidified incubator. MDM were then cocultured with 
HaCaT or BxPC3 target cells for 48 h at an effector:target (E:T) 
cell ratio of 4:1 or 20:1 at 37°C in complete RPMI growth medium 
in a 5% CO2 humidified incubator. Cocultures (carried out in 
quadruplicates) were pulsed with 0.5 μCi/well of methyl-tritiated 
[3 H]-thymidine (Perkin Elmer) during the final 18 h of coculture. 
Cells were then harvested onto glass fiber filters (Connectorate 
AG) and the radioactivity of incorporated 3  H-thymidine was 
determined by a liquid scintillation counter (Perkin Elmer) and 
expressed as counts per minute (cpm). The data were normalized 
by subtracting the cpm of MDM cultured alone from the cpm of 
HaCaT- or BxPC3-MDM-cocultures. Results were reported as 
percentage of HaCaT or BxPC3 growth inhibition calculated as 
follows: [1 − (cpm of HaCaT- or BxPC3-MDM-cocultures/cpm 
of HaCaT or BxPC3 cells cultured alone)] × 100.
4Bazzi et al. Characterization of Mycobacteria-Differentiated Macrophages
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1253
Total rna isolation
Total RNA was purified from MDM using the RNeasy Plus kit 
(Qiagen) according to the manufacturer’s instructions. Concen-
trations of RNA samples were quantified using the NanoDrop 2000 
spectrophotometer (Thermofisher) according to the manufacturer’s 
protocol. Quality was assessed by computing RNA integrity numbers 
using the Agilent 2100 Bioanalyzer according to the manufacturer’s 
instructions.
Preparation of Whole-Transcriptome 
libraries, Templates, and rna-
sequencing (rna-seq)
Total RNA (800  ng) was ribosomal RNA depleted using the 
Low Input RiboMinus Eukaryote System v2 (Thermofisher) 
according to the manufacturer’s instructions. Samples were then 
vacuum concentrated and whole-transcriptome and barcoded 
libraries were prepared using the Ion Total RNA-Seq Kit v2 
(Thermofisher) according to the manufacturer’s instructions. 
Size distribution of samples was assessed using the Agilent 
2100 Bioanalyzer and 6000 RNA Pico kit. Library concentra-
tions were quantified using the Agilent DNA 1000 assay and 
the 2100 Bioanalyzer according to the manufacturer’s instruc-
tions. Barcoded whole-transcriptome libraries were diluted to 
a 66 pM concentration and combined in equal volumes (13 µl 
each, 26 µl total) for sequencing with two samples per template 
preparation. All template reactions were performed on the Ion 
Chef Instrument using the Ion PI Hi-Q Chef kit (Thermofisher) 
according to the manufacturer’s instructions. Reactions were 
loaded onto Ion PI Chips v3 (Thermofisher) for sequencing on an 
Ion Proton sequencer according to the manufacturer’s protocol.
rna-seq analysis
Alignment of reads was performed using Partek flow and a two-
step alignment procedure. Unaligned reads were first aligned 
(hg19) using the STAR algorithm (45). Following the first align-
ment, any unaligned reads were then realigned with Bowtie2 
version 2.1.0 (46). Reads from both alignment steps were then 
combined. Transcripts were then quantified using a modified 
version of the expectation-maximization (E/M) algorithm as 
described previously (47). Resultant reads per kilobase per 
million (RPKM) values were first processed by adding a pseu-
docount to all values with RPKM < 1.0 followed by log (base 2) 
transformation and quantile normalization.
A fixed-effects models with ANOVA was used to identify 
transcripts significantly differentially expressed (n = 965, Table 
S1 in Supplementary Material) among GM-MDM, M-MDM, 
and Mob-MDM (P  <  0.05 and twofold change thresholds). 
Analysis was performed in the R language environment and 
using the BRB-Array tools developed by Richard Simon and the 
BRB-ArrayTools development team (48). Select transcripts were 
also assessed in pair-wise comparisons (e.g., GM-MDM com-
pared to M-MDM) using t-tests with random variance models. 
Unsupervised hierarchical clustering analysis was performed to 
identify, among the differentially expressed genes, those with 
different patterns of expression among the three MDM (49, 50). 
Functional pathways analysis, including gene set enrichment 
and gene-gene network analysis, of differentially expressed 
transcripts was performed using Ingenuity Pathways Analysis 
as described previously (51). Raw data were deposited into 
the gene expression omnibus under dataset series GSE102492 
(samples GSM2739484 to GSM2739495).
statistical analysis
Statistical analysis of data was performed using GraphPad 
Prism software (version 6; GraphPad Software). Data were 
presented as mean values ± SEM values. Statistical significance 
of differences between different MDM types was determined 
by one-way ANOVA test followed by the Tukey’s post hoc test 
for confirmation of significant differences in means among the 
different groups. P values <0.05 denoted statistical significance.
resUlTs
Phenotypic characterization of M-MDM, 
gM-MDM, and Mob-MDM
We observed the morphology of different MDM generated 
by the disparate methods of monocyte-to-Mφ differentiation. 
M-MDM, GM-MDM, and Mob-MDM predominantly exhibited 
a round-shaped morphology with few spindle-shaped cells coex-
isting in cultures (Figure 1A). We then sought to compare and 
contrast the expression levels of various prototypic cell surface 
receptors on M-MDM, GM-MDM, and Mob-MDM. This group 
of surface receptors was selected on the basis of previous stud-
ies that described these validated receptors as selective markers 
for unpolarized/steady-state human M-MDM and GM-MDM 
(13, 16). Figure 1B shows representative flow cytometry plots 
analyzing the differential expression of CD14, CD36, and MHC 
class I on different MDM types. Our analysis revealed that 
M-MDM displayed higher surface expression levels (% and MFI 
of positive cells) of the M2-like markers CD14, CD36, CD163, 
and CD195, relative to GM-MDM and Mob-MDM, which 
both exhibited comparable levels of CD195 (Figures 2A,B). In 
contrast, Mob-MDM exhibited the lowest surface expression 
levels of CD36, whereas GM-MDM exhibited the lowest surface 
expression levels of CD14 and CD163 (Figures 2A,B). Of note, 
a small subset of GM-MDM (20%) expressed the DC marker, 
CD1a (52), which was expressed at extremely low levels (<1%) 
on both M-MDM and Mob-MDM (Figure 2A). Additionally, 
we noted that CD206 expression was significantly (P <  0.05) 
higher in GM-MDM compared to M-MDM and Mob-MDM 
(Figures 2A,B). We also probed the expression levels of other 
types of cell surface receptors. Although the percentage of 
MHC class I+ and MHC class II+ cells were similar among the 
three MDM types (Figure 2A), M-MDM exhibited significantly 
increased MFIs of both receptors (P <  0.05) cells compared 
to GM-MDM and Mob-MDM (Figure  2B). Also, M-MDM 
displayed significantly (P  <  0.05) higher percentage of cells 
positive for the costimulatory marker, CD86 (Figure 2A). On 
the other hand, Mob-MDM exhibited the highest percentage 
of cells positive for the costimulatory/activation marker, CD40 
(Figure 2A). It is worthwhile to note that we found no significant 
differences in the percentage of cells positive for the other 
FigUre 1 | Morphological and immunophenotypic characterization of monocyte-derived macrophages (MDM). Macrophage colony-stimulating factor MDM 
(M-MDM), granulocyte/macrophage colony-stimulating factor MDM (GM-MDM), and Mycobacterium obuense MDM (Mob-MDM) were generated as described 
above (see Materials and Methods). (a) The morphology of the three MDM types was analyzed using a light-phase microscope (200× magnification).  
(B) Representative flow cytometry plots from one healthy donor showing the surface expression of CD14, CD36 (presented as dot plots), and MHC class I 
(presented as histogram plots) on different MDM types (black dotted line histogram: isotype control; red line histogram: GM-MDM; black line histogram: Mob-MDM; 
green line histogram: M-MDM). Numbers within lower and upper right quadrants of dot plots correspond to the percentage of receptor-positive MDM out of the total 
MDM population. Numbers next to histogram plots indicate the geometric mean fluorescence intensity (MFI) of receptor-positive MDM. SSC-H, side scatter height.
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costimulatory marker, CD80, or for the chemokine receptor 7, 
CD197, between the three MDM types (Figures 2A,B). We also 
studied the expression of different Fc receptors on M-MDM, 
GM-MDM, and Mob-MDM, generated from a smaller number 
of donors (n  =  5). Statistically significant differences were 
reflected by a lower CD16 expression (% of positive cells) in 
FigUre 2 | Expression levels of surface receptors on monocyte-derived macrophages (MDM). Macrophage colony-stimulating factor MDM (M-MDM), granulocyte/
macrophage colony-stimulating factor MDM (GM-MDM), and Mycobacterium obuense MDM (Mob-MDM) were generated as described above (see Materials and 
Methods). The expression levels of select cell surface receptors were measured by flow cytometry. Column bars represent mean values of the (a) percentage (%) 
and (B) geometric mean fluorescence intensity (MFI) of receptor-positive MDM from at least seven independent healthy donors. Error bars represent SEM. 
Statistically significant differences in receptor expression among the MDM were determined by one-way ANOVA followed by the Tukey’s post hoc test (*P < 0.05; 
**P < 0.01).
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Mob-MDM versus M-MDM, a higher CD64 expression (% of 
positive cells) in Mob-MDM versus GM-MDM, and a higher 
CD32 expression (% and MFI of positive cells) in M-MDM as 
compared to GM-MDM (Figure S1 in Supplementary Material). 
Our findings point to differential expression of prototypic cell 
surface markers in MDM differentiated in the presence of HK 
M. obuense relative to MDM generated by GM-CSF and M-CSF.
chemokine and cytokine Profiles of 
M-MDM, gM-MDM, and Mob-MDM
We next evaluated the profiles of a panel of spontaneously 
released proinflammatory and anti-inflammatory chemokines 
and cytokines, over a 24  h culture period, in M-MDM, 
GM-MDM, and Mob-MDM cultures. Both GM-MDM and 
Mob-MDM exhibited relatively higher levels of M-CSF com-
pared with M-MDM, albeit not reaching statistical significance 
(Figure 3). We also noted that the levels of the chemokine CCL22 
were significantly higher in both GM-MDM and Mob-MDM 
relative to M-MDM (4.5- and 3.8-fold, respectively; Figure 3). 
Unlike M-MDM and GM-MDM, Mob-MDM secreted signifi-
cant (P < 0.05) levels of the proinflammatory cytokines, IL-6, 
TNF-α, and CXCL8/IL-8 (Figure 3). Of note, while CCL2 was 
lowest in Mob-MDM and highest in M-MDM, CCL5 exhib-
ited reciprocal patterns of expression, i.e., the chemokine was 
significantly highest in Mob-MDM and lowest in the M-MDM 
type. Also, levels of secreted CXCL9 were only detected in 
supernatants of Mob-MDM, albeit CXCL9 levels were found 
to originate from only two out of the eight donors (Figure 3). 
Additionally, we did not detect IL-10, IL-12 (p40), IL-12 (p70), 
IL-23 (p19/p40), TGF-β1, and VEGF in M-MDM, GM-MDM, 
and Mob-MDM supernatants (data not shown). We then 
examined nitric oxide (NO) production through measuring its 
stable end-product nitrite in MDM culture supernatants. This 
FigUre 3 | Chemokine and cytokine release by macrophage colony-stimulating factor monocyte-derived macrophages (M-MDM), granulocyte/macrophage 
colony-stimulating factor MDM (GM-MDM), and Mycobacterium obuense MDM (Mob-MDM). M-MDM, GM-MDM, and Mob-MDM were generated as described 
above (see Materials and Methods). Chemokine and cytokine levels were determined in MDM culture supernatants by ELISA. Column bars represent mean values  
of chemokine or cytokine concentration in MDM culture supernatants of at least three healthy independent donors. Error bars represent SEM. Statistically significant 
differences in chemokine/cytokine release levels were determined by one-way ANOVA followed by the Tukey’s post hoc test (*P < 0.05; **P < 0.01).
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analysis revealed that there were no detectable levels of nitrite 
found in culture supernatants of the three MDM types (data not 
shown). Our data strongly point to chemokine/cytokine profiles 
and immune phenotypes that are associated with Mob-MDM 
relative to both M-MDM and GM-MDM.
Differential cytostatic activities of 
M-MDM, gM-MDM, and Mob-MDM
We next examined the cytostatic activities of M-MDM, 
GM-MDM, and Mob-MDM against the immortalized human 
keratinocyte cell line, HaCaT and the human ductal pancre-
atic adenocarcinoma cell line, BxPC3. Cell growth inhibition 
of both HaCaT and BxPC3 cells was apparent after 48  h of 
coculture with the different MDM types at 4:1 effector:target 
(E:T) ratio and became more pronounced at 20:1 (E:T) ratio 
(Figures 4A,B). At both E:T ratios, GM-MDM and Mob-MDM 
demonstrated similar growth inhibitory effects on HaCaT cells 
whereby these effects were significantly higher (P < 0.05) than 
those exerted by M-MDM (Figure 4A). At 4:1 (E:T) ratio, there 
were no significant differences in BxPC3 growth inhibition 
among M-MDM, GM-MDM, and Mob-MDM, whereas at 20:1 
(E:T) ratio, there was significantly elevated growth inhibition 
of BxPC3 cells cocultured with GM-MDM and Mob-MDM 
relative to M-MDM (Figure 4B).
comparative rna-seq analysis of Mob-
MDM, M-MDM, and gM-MDM
Our findings on the differential cell surface receptor and 
chemokine/cytokine profiles as well as tumor cell cytostatic 
activity of Mob-MDM relative to MDM-MDM and GM-MDM 
prompted us to compare and contrast genome-wide expression 
between the three MDM groups. We performed RNA-Seq, using 
the Ion Torrent Proton platform, of Mob-MDM, M-MDM, 
and GM-MDM derived from four donors (n =  12 samples). 
On average, we sequenced approximately 36 million reads per 
sample and achieved 90% uniformity of coverage. Following 
alignment and transcriptome quantification, we employed a 
fixed effects model and ANOVA with a statistical threshold of 
P < 0.05 and a twofold change cutoff to identify transcripts that 
were differentially expressed among the three groups (n = 965, 
Table S1 in Supplementary Material). Of the 965 transcripts, we 
confirmed markers that are known (19, 20) to be differentially 
expressed between M-MDM and GM-MDM including the 
transmembrane receptors CD36, CD163, MRC-1 (CD206), 
and STAB1, the cytokine TNFSF13, the chemokine CCL2, the 
peptidase ADAMDEC1 and others such as SEPP1 surface recep-
tors (Table S2 in Supplementary Material). We then performed 
unsupervised hierarchical clustering analysis to delineate 
subgroups or clusters of genes with differential patterns of 
FigUre 4 | Analysis of antiproliferative effects of the monocyte-derived 
macrophages (MDM) on immortalized and malignant epithelial cells. 
Macrophage colony-stimulating factor MDM (M-MDM), granulocyte/
macrophage colony-stimulating factor MDM (GM-MDM), and Mycobacterium 
obuense MDM (Mob-MDM) were generated as described above (and see 
Materials and Methods). The MDM were cocultured with HaCaT  
(a) or BxPC3 (B) cells at effector to target (E:T) cell ratios of 4:1 and 20:1 for 
48 h. Cell proliferation was next determined by tritiated [3H]-thymidine 
incorporation assay and data were expressed as counts per minute (cpm). 
Percentage (%) of cell growth inhibition was calculated as described in the 
Section “Materials and Methods.” Column bars represent mean values of the 
% of cell growth inhibition induced by MDM from five (a) and four  
(B) independent healthy donors, respectively. Each experiment employing 
MDM from different donors were performed in quadruplicates. Error bars 
represent SEM. Statistically significant differences in cytostatic activity were 
determined by one-way ANOVA test followed by the Tukey’s post hoc test 
(*P < 0.05; **P < 0.01).
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expression amongst the three MDM. Two-dimensional hier-
archical clustering of both transcripts and samples revealed 
that Mob-MDM clustered separately from both M-MDM and 
GM-MDM (Figure  5). Of note, this analysis revealed two 
clusters of transcripts that exhibited lowest and highest relative 
expression in Mob-MDM compared with both M-MDM and 
GM-MDM (Figure 5). Among the two clusters, further analysis 
revealed 256 transcripts that were differentially expressed in 
Mob-MDM relative to both M-MDM and GM-MDM (Table S3 
in Supplementary Material).
Following the differential expression and clustering analysis, 
we were prompted to understand functional pathways and 
gene sets that are linked to Mob-MDM. Gene ontology analysis 
revealed that the Mob-MDM-associated transcripts comprised 
chemokines/cytokines, enzymes such as peptidases, phosphatases, 
and kinases as well as transmembrane receptors and transcrip-
tion regulators (Table S3 in Supplementary Material). Select 
chemokines and cytokines, namely CXCL8/IL-8 and TNF-α, 
were confirmed by ELISA to be expressed in Mob-MDM (Figure 
S2 in Supplementary Material). Pathways analysis underscored 
canonical signaling pathways that were significantly modulated 
in Mob-MDM relative to M-MDM and GM-MDM including 
nitric oxide signaling, acute phase response, TREM1, and IL-6 
(all P <  0.05; Table S4 in Supplementary Material). Gene set 
enrichment analysis predicted significant activation or inhibition 
(z-score ≥ 2 or ≤−2, respectively) of signaling modules in Mob-
MDM relative to both GM-MDM and M-MDM but not between 
the latter two MDM types (all P < 0.05; Table S5 in Supplementary 
Material). These included marked activation of cytokines/
chemokines such as interferon-gamma (IFNG, z-score = 4.98) and 
of intracellular receptors such as nucleotide-binding oligomeriza-
tion domain-containing protein 2 (NOD2, z-score = 3.14) with 
P values < 0.0001 (Figure 6). The gene set and network analysis 
also underscored biological functions such as increased dif-
ferentiation of mononuclear leukocytes (z-score = 3.0), elevated 
movement of mononuclear leukocytes (z-score  =  4.41), and 
phagocytes (z-score =  4.24) that were significantly modulated 
(all P  <  0.0001) in Mob-MDM relative to both GM-MDM 
and M-MDM but not among the latter two MDM (Table S6 in 
Supplementary Material). Our coupled RNA-Seq and functional 
pathways analysis point to functional gene expression programs 
in Mob-MDM that may underlie context-specific immunomodu-
latory effects of HK M. obuense.
DiscUssiOn
Heat-killed preparations of the mycobacterium M. obuense 
have demonstrated promise in the immunotherapeutic set-
ting in the clinic (41). However, there is much paucity in our 
knowledge either in the mechanisms of HK M. obuense as 
a driver of monocyte to Mφ differentiation or in its potential 
role in driving the polarization of human Mφ toward the 
M1-Mφ phenotype. Although it has been commonly reported 
that several bacteria can trigger the polarization of differenti-
ated Mφ toward the M1-Mφ phenotype (53), other types of 
bacteria were reported to induce specific M2 programs (54). 
In addition, different mycobacterial species have been shown 
to exhibit differential effects on differentiated Mφ. While viable 
M. tuberculosis cultured with differentiated Mφ was found 
to induce the gene expression of IL-6 and TNF-α, viable M. 
leprae failed to induce significant changes in gene expression 
levels of either cytokine (55). Moreover, the effects of viable M. 
tuberculosis on Mφ gene expression profiles were reported to be 
quite distinct from those induced by HK M. tuberculosis (56). To 
our knowledge, the present study is the first to demonstrate the 
ability of HK M. obuense to induce the differentiation of human 
monocytes into Mφ. Moreover, it provides the first phenotypic 
and genome-wide whole transcriptome characterization of 
Mob-MDM in comparison to unpolarized/steady-state M-MDM 
and GM-MDM. Our results underscored surface receptor and 
cytokine protein profiles that accentuate the immunophenotype 
-5 0 +5
GM-MDM M-MDMMob-MDM
highest in Mob-MDM 
lowest in Mob-MDM 
FigUre 5 | Whole-transcriptome analysis of monocyte-derived macrophages (MDM). Macrophage colony-stimulating factor MDM (M-MDM), granulocyte/
macrophage colony-stimulating factor MDM (GM-MDM), and Mycobacterium obuense MDM (Mob-MDM) were generated as described above (and see Materials and 
Methods) from four healthy donors (n = 12). Total RNA was isolated and then sequenced using the Ion Torrent platform (as described in the Section “Materials and 
Methods”). Sequence alignment followed by quantification of transcriptomes was performed as described in the Section “Materials and Methods.” Transcripts 
(n = 965) differentially expressed between the three MDM were identified based on a fixed-effects model with ANOVA and analyzed by hierarchical clustering. 
Columns represent samples and rows constitute the differentially expressed transcripts (yellow, upregulated compared with the median sample; blue, relatively 
downregulated).
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in Mob-MDM relative to the other two Mφ types. Transcriptome 
profiling by RNA-Seq, coupled with functional pathways analysis, 
pointed to activated (by virtue of gene expression) gene sets and 
networks indicative of an overall augmented proinflammatory 
M1-like Mφ phenotype in Mob-MDM relative to both M-MDM 
and GM-MDM. Our integrative study, probing for both protein 
and transcript profiles, provides molecular insights that may 
underlie immunomodulatory effects of HK M. obuense and that 
may be used as markers of response to HK M. obuense-based 
immunotherapy.
In the present study, M-MDM and GM-MDM revealed 
distinct expression patterns of a group of surface receptors 
which were concordant with those reported in previous studies 
(13, 16, 17, 57, 58). We noted significant differences in receptor 
expression profiles between M-MDM and GM-MDM with the 
former Mφ comprising elevated levels of CD14, CD32, CD163, 
and MHC class II and the latter Mφ depicting augmented 
CD206 expression. On the other hand, our data, as well as others 
(13, 18, 59), demonstrated that M-MDM and GM-MDM exhibit 
similar expression patterns of another group of surface receptors 
comprising CD16, CD40, CD64, and CD86. Nevertheless, these 
findings were not in agreement with other reports (16, 58, 60) 
and such discrepancies in cell surface receptor expression pat-
terns between M-MDM and GM-MDM might be attributed to 
FigUre 6 | Predicted activated gene-gene networks mediated by interferon-gamma (IFNG) and nucleotide-binding oligomerization domain-containing protein 2 
(NOD2) in Mycobacterium obuense monocyte-derived macrophages (Mob-MDM). Macrophage colony-stimulating factor MDM (M-MDM), granulocyte/macrophage 
colony-stimulating factor MDM (GM-MDM), and Mob-MDM were generated as described above (and see Materials and Methods) from four healthy donors (n = 12) 
and profiled by RNA-seq. Transcripts (n = 256) that were significantly differentially expressed in Mob-MDM relative to both M-MDM and GM-MDM, were interrogated 
by pathways, gene–gene network and gene set enrichment analyses using the commercially available software Ingenuity Pathways Analysis (IPA). Gene–gene 
network analysis demonstrated predicted activation (indicated by the orange color) of (a) interferon-gamma (IFNG) and (B) nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2) along with upregulation (red color) of downstream genes in the IFNG- and NOD2-mediated networks in Mob-MDM relative to 
both GM-MDM and M-MDM.
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variations in culture conditions adopted in different studies, and 
in particular the concentration of M-CSF and GM-CSF used as 
well as the duration of the differentiation period. It is important to 
note that we detected a subpopulation (~20%) in GM-MDM that 
expressed CD1a. This cell surface receptor is typically expressed 
on monocyte-derived DCs differentiated in the presence of 
GM-CSF and IL-4 (61). Of note, previous studies (16, 21) simi-
larly demonstrated elevated CD1a expression on GM-MDM. In 
Mob-MDM, we noted markedly diminished surface expression 
of CD36, a class B scavenger receptor implicated in the uptake of 
oxidized low density lipoprotein, sensing of bacteria and clear-
ance of apoptotic cells (62), when compared to M-MDM and 
GM-MDM. It is worthwhile to mention that CD36 expression 
was also lower in GM-MDM compared to M-MDM with the 
receptor being the highest in the latter Mφ. Our findings are 
consistent with previous studies suggesting CD36 to function as 
a prototypic M2-Mφ marker (63). Of note, previous studies have 
suggested proinflammatory cues mediated by CD36-mediated 
signaling (64, 65). Our immunophenotypic findings point to cell 
surface profiles in Mob-MDM that are indicative of proinflam-
matory signaling in these immune cells following differentiation 
by HK M. obuense.
Along with the immunophenotypic analysis, we assessed 
spontaneous cytokine release profiles of the three MDM types. 
In line with previous studies, M-MDM spontaneously secreted 
higher levels of CCL2 (13, 14, 19) and lower levels of CCL22 
(13, 16) as compared to unpolarized GM-MDM. We did not 
detect any spontaneous production of IL-6, IL-12 (p40), IL-12 
(p70), IL-23 (p19/p40), or TNF-α in unpolarized M-MDM and 
GM-MDM culture supernatants and this in agreement with 
previously published results (13–15, 18, 23, 58). Although IL-10 
has been previously reported to be spontaneously released at 
extremely low levels by M-MDM (17, 23, 58), we and others 
(14, 15) did not detect any spontaneous IL-10 secretion by 
M-MDM. In addition, CXCL9, mainly secreted by polarized 
GM-MDM (M1-Mφ) (66), was not detected in unpolarized 
GM-MDM culture supernatants. Compared with M-MDM 
and GM-MDM, Mob-MDM exhibited significantly elevated 
spontaneous release of the proinflammatory cytokines IL-6 and 
TNF-α and chemokine CXCL8/IL-8. The present findings are 
in line with our previous report interrogating cytokine release 
in whole blood exposed to HK M. obuense (43). Together, these 
findings highlight the potential of HK M. obuense preparation 
to activate cells of the innate immune system, and suggest 
probable signaling molecules in mycobacteria that are casually 
linked to release of proinflammatory chemokines/cytokines in 
these cells. Indeed, mycobacterial-associated molecules, such as 
heat shock proteins and muramyl peptides, have been previously 
demonstrated to trigger multiple proinflammatory chemokines 
and cytokines (67–70). It is worthwhile to note that CXCL8/
IL-8 was shown to be a potent neutrophil chemoattractant (71). 
In this context, it is plausible to surmise that Mob-MDM exhibit 
significant neutrophil chemoattractant properties, e.g., in an 
infection setting. An additional salient feature of Mob-MDM 
that we observed was release of attenuated CCL2 levels in com-
parison with M-MDM and GM-MDM. CCL2 is a chemokine 
shown to help promote Th2 polarization by dampening Mφ 
activation and proinflammatory cytokine production (72). 
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In studies surveying neoplasm pathology, CCL2 levels are 
positively associated with tumor-associated Mφ that typically 
exhibit an M2-like phenotype (14, 73). Our findings render the 
supposition that, in sharp contrast to M-CSF and GM-CSF, HK 
M. obuense resulted in differentiated Mφ (Mob-MDM) with 
elevated cytokine release signatures indicative of a proinflam-
matory M1-like Mφ phenotype.
In this study, we found that both Mob-MDM and GM-MDM 
exhibited higher antiproliferative effects against human pancre-
atic cancer cells, BxPC3, when compared to M-MDM. Similar 
differential cytostatic activities of GM-MDM and M-MDM have 
been previously reported when evaluated against colorectal 
cancer cells (74). In contrast, both M-MDM and GM-MDM 
did not demonstrate antitumor cell cytostatic effects in previ-
ous reports studying different osteosarcoma cell lines (75). 
It is noteworthy, that we found similar antiproliferative effects 
by Mob-MDM and GM-MDM in immortalized keratinocyte 
epithelial cells (HaCaT) suggesting that the antitumor effects of 
such Mφ (Mob-MDM) may extend to the premalignant setting. 
Of note, the proinflammatory cytokine TNFα, which we found 
to be secreted preferentially by Mob-MDM, was previously 
reported to inhibit the proliferation of various pancreatic cancer 
cell lines in vitro (76, 77). It is reasonable to speculate that soluble 
factor(s) released by the Mφ (e.g., lymphotoxin-β and TNFα) 
may underlie the elevated cytostatic properties displayed by 
Mob-MDM and GM-MDM. However, it cannot be neglected 
that additional mechanisms may mediate the antiproliferative 
effects of Mob-MDM and GM-MDM, such as the interaction 
(and signaling thereof) between tumor cells and Mφ warranting 
future studies to probe this hypothesis. It is worthwhile to men-
tion that a recent phase II clinical trial investigated the potential 
immunotherapeutic use, in combination with chemotherapy, of 
HK M. obuense in pancreatic cancer patients (41). In this reported 
clinical study by Dalgleish et al., HK M. obuense was shown to 
exhibit immunotherapeutic effects when given in combination 
with chemotherapy, in pancreatic cancer patients with metastatic 
disease, a patient subpopulation for which there are no current 
targeted/immunotherapeutic treatment strategies. Our mecha-
nistic findings and the aforementioned recent clinical report 
underscore the promising potential of immunotherapeutic 
strategies utilizing HK M. obuense, for advanced malignancies.
We performed RNA-Seq analysis to compare and contrast 
genome-wide expression among the three MDM. Our sequenc-
ing analysis pointed to 965 transcripts that were significantly 
differentially expressed among Mob-MDM, GM-MDM, and 
M-MDM. Among those, profiles significantly modulated 
between M-MDM and GM-MDM comprised transcripts 
previously reported to be higher (e.g., CD163 and STAB1) and 
lower (e.g., CCL24 and MRC1/CD206) in M-MDM (19, 20) 
relative to GM-MDM. We also found 256 transcripts linked to 
Mob-MDM phenotype as they were not modulated between 
M-MDM and GM-MDM. These transcripts likely indicate that 
M. obuense-driven differentiation resulted in an Mφ phenotype 
that expresses significantly higher levels of certain markers (Table 
S3 in Supplementary Material), as compared to GM-MDM, that 
are frequently associated with classically activated M1-Mφ. Such 
markers include, among others, TNF, IL-6, CCR7, nicotinamide 
phosphoribosyltransferase (NAMPT), formyl peptide receptor 
1 (FPR1), and chemokine-like receptor 1 (CMKLR1) (13, 14, 
78–81). Moreover, the Mob-MDM selective transcripts included 
a battery of molecules which potentiate the antimicrobial activity 
of innate immune Mφ including, among others, several comple-
ment components, cytokines and chemokines, G protein-coupled 
receptors such as FPR1 (82) and CYP27B1. CYP27B1 encodes 
25-hydroxyvitamin D3 1-α-hydroxylase which generates the bio-
active form of 25-hydroxyvitamin D3, namely 1,25-dihydroxyvi-
tamin D3. This metabolite activates vitamin D receptor, thereby 
inducing release of antimicrobial peptides (83) and triggering the 
antimicrobial activity of Mφ against M. tuberculosis (84).
Our RNA-Seq profiling coupled with pathways and gene-gene 
network analysis pointed to various topological functional gene 
networks predicted to be significantly and selectively modulated 
in Mob-MDM including, among others, gene-gene networks 
mediated by the proinflammatory cytokine, IFNG (85), and 
the intracellular pattern recognition receptor, nucleotide oli-
gomerization domain 2 (NOD2). Notably, both the IFNG- and 
NOD2-mediated networks comprised proinflammatory markers 
including IL1B, CXCL8, and TNF. Previous work has shown that 
the NOD2 receptor recognizes the N-glycolyl muramyl dipeptide 
present in mycobacteria (86), thus implicating NOD2 as one of 
the candidate receptors that may be involved in mediating the 
immunomodulatory effects of HK M. obuense. It is worthwhile to 
mention, as indicated above, that we had found elevated expres-
sion of the protein products of CXCL8 and TNF in Mob-MDM. 
Our orthogonal analysis provide supportive framework for the 
finding of proinflammatory gene profiles in Mob-MDM. Our 
gene set enrichment analysis also demonstrated that various toll-
like receptors (TLRs) were significantly and selectively predicted 
to be activated in Mob-MDM. Previous studies have shed light on 
critical roles for innate cell TLRs in mediating recognition of and 
response to mycobacterial antigens (87, 88). For instance, TLR-2 
(as a heterodimer with either TLR-1 or TLR-6) -4, and -9 have 
been shown to be engaged in sensing various mycobacterial cell 
wall components such as glycolipids, glycoproteins, lipoproteins, 
and unmethylated CpG motifs in mycobacterial DNA (87, 88). 
In addition, studies from our group have underscored crucial roles 
for TLR-1 and -2 in mediating HK M. obuense-induced modula-
tion of surface receptor expression on human monocytes (43) and 
DCs (44). Differentiation of monocytes into macrophages has 
been previously associated with ligation and activation of certain 
TLRs including TLR-2/1 (89). This could explain, at least in part, 
the ability of HK M. obuense to drive monocyte differentiation 
into Mφ. Our coupled RNA-Seq and functional pathways analysis 
provide insights into transcriptional programs in Mob-MDM that 
resemble, but not restricted to, the classically–activated M1-like 
Mφ phenotype.
All in all, our integrative immunophenotypic and genome-
wide transcriptomic study reveals cell surface profiles, 
chemokine/cytokine release patterns, gene expression profiles 
and gene-gene networks in Mob-MDM that are quite different 
from those observed in upolarized/steady-state GM-MDM and 
M-MDM. Our study also sheds light on contextual genome-
wide signaling cues in Mob-MDM that accentuate how HK 
M.  obuense may program innate immune cells toward an 
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elevated proinflammatory M1-like Mφ phenotype. Thus, one 
potential implication of our findings would be the use of Mob-
MDM in an immunotherapeutic approach such as adoptive cell 
transfer of macrophages to treat cancer patients. In fact, adoptive 
cellular immunotherapy in cancer patients using autologous 
macrophages generated in  vitro from blood monocytes has 
been extensively reported, but with limited success (90–93). Our 
present study warrants future investigations to further probe the 
functional responses of Mob-, M-, and GM-MDM following 
activation with an inflammatory stimulus in the presence or 
absence of a type 1 cytokine.
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